PE20091711A1 - Derivados de amidas del acido 3-trifluorometil-pirazin-2-carboxilico como agentes para aumentar el hdl-colesterol - Google Patents

Derivados de amidas del acido 3-trifluorometil-pirazin-2-carboxilico como agentes para aumentar el hdl-colesterol

Info

Publication number
PE20091711A1
PE20091711A1 PE2009000467A PE2009000467A PE20091711A1 PE 20091711 A1 PE20091711 A1 PE 20091711A1 PE 2009000467 A PE2009000467 A PE 2009000467A PE 2009000467 A PE2009000467 A PE 2009000467A PE 20091711 A1 PE20091711 A1 PE 20091711A1
Authority
PE
Peru
Prior art keywords
pirazin
cholesterol
trifluoromethyl
amidas
cycloalkyl
Prior art date
Application number
PE2009000467A
Other languages
English (en)
Inventor
Paul Hebeisen
Stephan Roever
Constantinos G Panousis
Matthew Wright
Original Assignee
Hoffmann La Roche
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Hoffmann La Roche filed Critical Hoffmann La Roche
Publication of PE20091711A1 publication Critical patent/PE20091711A1/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D241/00—Heterocyclic compounds containing 1,4-diazine or hydrogenated 1,4-diazine rings
    • C07D241/02—Heterocyclic compounds containing 1,4-diazine or hydrogenated 1,4-diazine rings not condensed with other rings
    • C07D241/10—Heterocyclic compounds containing 1,4-diazine or hydrogenated 1,4-diazine rings not condensed with other rings having three double bonds between ring members or between ring members and non-ring members
    • C07D241/14—Heterocyclic compounds containing 1,4-diazine or hydrogenated 1,4-diazine rings not condensed with other rings having three double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D241/20—Nitrogen atoms
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/04—Anorexiants; Antiobesity agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/06—Antihyperlipidemics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/12—Antihypertensives
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D241/00—Heterocyclic compounds containing 1,4-diazine or hydrogenated 1,4-diazine rings
    • C07D241/02—Heterocyclic compounds containing 1,4-diazine or hydrogenated 1,4-diazine rings not condensed with other rings
    • C07D241/10—Heterocyclic compounds containing 1,4-diazine or hydrogenated 1,4-diazine rings not condensed with other rings having three double bonds between ring members or between ring members and non-ring members
    • C07D241/14—Heterocyclic compounds containing 1,4-diazine or hydrogenated 1,4-diazine rings not condensed with other rings having three double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D241/24—Carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links

Landscapes

  • Chemical & Material Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Veterinary Medicine (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Diabetes (AREA)
  • Hematology (AREA)
  • Obesity (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Urology & Nephrology (AREA)
  • Vascular Medicine (AREA)
  • Emergency Medicine (AREA)
  • Endocrinology (AREA)
  • Child & Adolescent Psychology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)

Abstract

REFERIDA A UN DERIVADO DE PIRAZINA DE FORMULA (I), DONDE R1 ES CICLOALQUILO C3-C7 OPCIONALMENTE SUSTITUIDO POR OH, HIDROXIALQUILO C1-C7 O CH2-CR9R10-CICLOALQUILO C3-C7; R9 ES H O ALQUILO C1-C7; R10 ES H U OH; R2 ES H; R3 ES CICLOALQUILO C3-C7, ALCOXIALQUILO C1-C7, HALOGENOALQUILO C1-C7, ENTRE OTROS; R4 Y R8 SON CADA UNO H O HALO; R5, R6 Y R7 SON CADA UNO H, ALQUILO C1-C7, ALCOXI C1-C7, ENTRE OTROS. SON COMPUESTOS PREFERIDOS: (2-CICLOPROPIL-2-HIDROXI-PROPIL)AMIDA DEL ACIDO 6-(4-CLORO-FENIL)-5-(2,2,2-TRIFLUORO-ETOXI)-TRIFLUOROMETIL-PIRAZIN-2-CARBOXILICO, ((1R,2R)-2-HIDROXI-CICLOHEXIL)-AMIDA DEL ACIDO 6-(4-CLORO-FENIL)-5-CICLOPROPILMETOXI-3-TRIFLUOROMETIL-PIRAZIN-2-CARBOXILICO, (2-CICLOPROPIL-2-HIDROXI-PROPIL)-AMIDA DEL ACIDO 6-(4-CLORO-FENIL)-5-CICLOPROPILMETOXI-3-TRIFLUOROMETIL-PIRAZIN-2-CARBOXILICO, ENTRE OTROS. TAMBIEN ESTE REFERIDO A UNA COMPOSICION FARMACEUTICA. DICHOS COMPUESTOS AUMENTAN EL HDL-COLESTEROL Y SON UTILES EN EL TRATAMIENTO DE LA DISLIPIDEMIA, ATEROSCLEROSIS, HIPERTRIGLICERIDEMIA, ENTRE OTRAS
PE2009000467A 2008-03-31 2009-03-30 Derivados de amidas del acido 3-trifluorometil-pirazin-2-carboxilico como agentes para aumentar el hdl-colesterol PE20091711A1 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
EP08153802 2008-03-31

Publications (1)

Publication Number Publication Date
PE20091711A1 true PE20091711A1 (es) 2009-11-13

Family

ID=40585575

Family Applications (1)

Application Number Title Priority Date Filing Date
PE2009000467A PE20091711A1 (es) 2008-03-31 2009-03-30 Derivados de amidas del acido 3-trifluorometil-pirazin-2-carboxilico como agentes para aumentar el hdl-colesterol

Country Status (14)

Country Link
US (1) US8088920B2 (es)
EP (1) EP2271632B1 (es)
JP (1) JP5243596B2 (es)
KR (1) KR101307066B1 (es)
CN (1) CN101981015B (es)
AR (1) AR071111A1 (es)
AU (1) AU2009231376A1 (es)
CA (1) CA2718645A1 (es)
ES (1) ES2408961T3 (es)
IL (1) IL208022A0 (es)
MX (1) MX2010009999A (es)
PE (1) PE20091711A1 (es)
TW (1) TW200944514A (es)
WO (1) WO2009121741A1 (es)

Families Citing this family (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP2450350A1 (en) * 2006-10-04 2012-05-09 F. Hoffmann-La Roche AG 3-Pyridinecarboxamide and 2-pyrazinecarboxamide derivatives as HDL-cholesterol raising agents
WO2012031817A1 (en) 2010-09-09 2012-03-15 F. Hoffmann-La Roche Ag Determination of abca1 protein levels in cells
US8410107B2 (en) * 2010-10-15 2013-04-02 Hoffmann-La Roche Inc. N-pyridin-3-yl or N-pyrazin-2-yl carboxamides
US8669254B2 (en) 2010-12-15 2014-03-11 Hoffman-La Roche Inc. Pyridine, pyridazine, pyrimidine or pyrazine carboxamides as HDL-cholesterol raising agents
EP2567959B1 (en) 2011-09-12 2014-04-16 Sanofi 6-(4-hydroxy-phenyl)-3-styryl-1h-pyrazolo[3,4-b]pyridine-4-carboxylic acid amide derivatives as kinase inhibitors
US9403808B2 (en) * 2011-10-28 2016-08-02 Hoffmann-La Roche Inc. Pyrazine derivatives

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4293552A (en) 1978-02-27 1981-10-06 Eli Lilly And Company Novel 1-(mono-o-substituted benzoyl)-3-(substituted pyrazinyl) ureas
CA2454059A1 (en) * 2001-07-19 2003-01-30 Cv Therapeutics, Inc. Substituted piperazine compounds and their use as fatty acid oxidation inhibitors
BRPI0609685A2 (pt) 2005-04-06 2010-04-20 Hoffmann La Roche compostos, processo para a sua manufatura, composições farmacêuticas que os compreendem, método para tratamento e/ou profilaxia de enfermidades que estão associados com a modulação de receptores de cb1, e utilização dos mesmos
US7629346B2 (en) 2006-06-19 2009-12-08 Hoffmann-La Roche Inc. Pyrazinecarboxamide derivatives as CB1 antagonists
US7781593B2 (en) 2006-09-14 2010-08-24 Hoffmann-La Roche Inc. 5-phenyl-nicotinamide derivatives
EP2450350A1 (en) 2006-10-04 2012-05-09 F. Hoffmann-La Roche AG 3-Pyridinecarboxamide and 2-pyrazinecarboxamide derivatives as HDL-cholesterol raising agents
EP2076499B1 (en) 2006-10-04 2010-05-12 F.Hoffmann-La Roche Ag Pyrazine-2-carboxamide derivatives as cb2 receptor modulators

Also Published As

Publication number Publication date
KR101307066B1 (ko) 2013-09-11
JP2011516445A (ja) 2011-05-26
AR071111A1 (es) 2010-05-26
US20090247550A1 (en) 2009-10-01
CN101981015A (zh) 2011-02-23
MX2010009999A (es) 2010-09-30
TW200944514A (en) 2009-11-01
ES2408961T3 (es) 2013-06-24
JP5243596B2 (ja) 2013-07-24
KR20100119819A (ko) 2010-11-10
EP2271632B1 (en) 2013-04-17
IL208022A0 (en) 2010-12-30
AU2009231376A1 (en) 2009-10-08
US8088920B2 (en) 2012-01-03
WO2009121741A1 (en) 2009-10-08
EP2271632A1 (en) 2011-01-12
CA2718645A1 (en) 2009-10-08
CN101981015B (zh) 2013-08-21

Similar Documents

Publication Publication Date Title
PE20190709A1 (es) Derivado de pirazolopiridinaque tiene el efecto agonista del receptor de glp-1
PE20091711A1 (es) Derivados de amidas del acido 3-trifluorometil-pirazin-2-carboxilico como agentes para aumentar el hdl-colesterol
PE20171737A1 (es) Derivados de quinazolinona biciclicos
PE20170325A1 (es) Compuestos y composiciones como agonistas del receptor tipo toll
PE20091590A1 (es) Derivados de piridinilo y pirimidinilo sustituidos como moduladores del metabolismo y para tratar trastornos metabolicos
PE20160843A1 (es) Pirrolidinonas herbicidas
PE20151001A1 (es) Alcoxipirazoles como activadores de guanilato ciclasa soluble
PE20080150A1 (es) Derivados de piridinona n-aril y n-heteroaril sustituidos como antagonistas del receptor de la hormona concentradora de melanina (mch)
PE20130010A1 (es) Derivado de 1,3,4,8-tetrahidro-2h-pirido[1,2-a]pirazina como inhibidor de la integrasa del vih
PE20120690A1 (es) Derivados de 5-fluoropirimidinona
PE20091033A1 (es) Derivados de nicotinamida como agentes anticancerosos y su preparacion
PE20130311A1 (es) Composiciones y metodos para modular la via de senalizacion de wnt
PE20142019A1 (es) Nuevos derivados de acidos indaniloxidihidrobenzofuranilaceticos y sus usos como agonistas del receptor gpr40
PE20130279A1 (es) Compuestos heteroarilo nitrogenados
PE20091901A1 (es) Activadores de glucoquinasa
PE20141067A1 (es) Compuestos para el tratamiento de la adiccion
PE20150224A1 (es) Inhibidores del nampt
PE20161407A1 (es) Piridina 5,6 disustituida -2-carboxamidas como agonistas del receptor canabinoide
PE20161444A1 (es) 1,2-ciclopentanos sustituidos como antagonistas del receptor de orexina
PE20150774A1 (es) Aminoquinolinas como inhibidores de cinasa
AR088609A1 (es) Derivados de n-[1-(piridil)ciclopropilmetil]heteroaril carboxamida utiles para combatir plagas en agricultura y veterinaria, composiciones farmaceuticas y veterinarias que los contienen y proceso para prepararlos
PE20151748A1 (es) Inhibidores de bace1
MX2020005738A (es) Derivados de glutarimida, uso de los mismos, composicion farmaceutica basada en los mismos y metodos para producir derivados de glutarimida.
PE20151060A1 (es) Nuevos derivados de pirazina como agonistas del receptor cb2
PE20142282A1 (es) Nuevos derivados de aril-quinolina

Legal Events

Date Code Title Description
FD Application declared void or lapsed